Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

and therefore pregnancy prevention measures must be in place for all women of child-bearing potential who receive alitretinoin. Within days after discontinuation of therapy, alitretinoin levels return to endogenous levels. In clinical studies the post-treatment contraceptive period was four weeks.

About Basilea Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX:BSLN). Basilea's fully integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including three investigational phase III drugs of which two have shown positive pivotal phase III results. The company is integrating commercialization into its organization, in a first step through co-promoting ceftobiprole with its partner Cilag GmbH International, a Johnson & Johnson company, in North America and major European countries.

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

General Information | Investor Relations
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:12/16/2009)... 16 Wound Management Technologies, Inc. ... provider of specialty medical products, announced today ... moving toward productization of its patented orthopedic ... anticipates products to be introduced in Q3 ... be a multi-billion dollar international market. ,, ...
(Date:12/16/2009)... CHICAGO, Dec. 16 A ... to manage the clinical review of specialty pharmaceuticals ... number of drugs reviewed while reducing costs. ,, ... technology company with health plan clients representing over ... WellPoint, Inc. (NYSE: WLP ), adapted ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
Breaking Medicine Technology:Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 2Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma 12872 1New Leadership Team at International Trachoma Initiative to Build Stronger Partnerships to Eliminate Blinding Trachoma 12872 2Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 1Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 2Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 3Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 4Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 5Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 6Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 7Sharing Miracles Television Program to Feature Legendary Rapper and Popular Actor Ice T 50540 8SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 1SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 2SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 3SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 4SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 5SIRIUS XMs Doctor Radio to Air July 4th Family Special 24 Hours About Our Kids 3A Why Kids Behave the Way They Do 50535 6
... Schering-Plough,Corporation (NYSE: SGP ) announced today ... from about 60 clinical studies relating,to its growing ... 44th,Annual Meeting of the American Society of Clinical ... Data will be presented on TEMODAR(R),(temozolomide) Capsules, CAELYX(R) ...
... Post-hoc analysis of pivotal studies presented at the National Lipid ... Association,s Annual Scientific Sessions, ... data from post-hoc analyses of three pivotal studies,demonstrated that the ... lower A1C in patients with type 2 diabetes,mellitus by 1% ...
Other Medicine Technology:About 60 Clinical Studies Regarding Schering-Plough's Oncology Compounds Will be Presented at ASCO 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6
(Date:12/17/2009)... litigators of complex personal injury and insurance cases, recognized for exceptional ... ... OK (Lexis Nexis) December 17, 2009 -- Jody Nathan , ... handling personal injury and insurance coverage disputes, has been named by ... the state of Oklahoma for 2009-2010., , ,Only five percent of ...
(Date:12/16/2009)... Health care sector revenue increased by ... from $1.66 trillion in 2007, according to new ... is classified under the North American Industry Classification ... ) ,, These figures come from the ... Assistance , a series of tables which provides ...
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a leading global ... its portfolio companies, Acclarent, Inc., has entered into ... Inc., a Johnson & Johnson company, in an ... estimated cash on hand at time of closing). ... and commercializing devices that address conditions affecting the ...
(Date:12/16/2009)... has never felt so good for "The Biggest Loser" ... means continuing to make smart choices everyday to help ... healthy choice that is an important part of living ... Every glass of milk has nine essential nutrients like ... blood pressure, and calcium and vitamin D for strong ...
(Date:12/16/2009)... result of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 ... is included in the final Fiscal Year 2010 Defense ... will research cancers, like colorectal cancer, that are not ... research programs run by the U.S. Army Medical Research ... in funding for this new cancer research program was ...
Breaking Medicine News(10 mins):Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3
... be spurring unrealistic expectations, study suggests , , WEDNESDAY, Nov. ... are far likelier than those in the 1970s to ... research shows. , They,re also much more likely to ... even though other research shows that today,s students do ...
... 12 Covenant House International is,releasing its First Annual Report ... outlook for their future. America,s kids in crisis will be,the ... on,Thursday, November, 20, 5:30 pm, in Times Square., "Over ... on our,streets every year. We were able to help 70,387 ...
... Indicates that a Patient,s or Loved One,s Hearing Loss Can ... to Inefficiency and Even Medical ... among those,who require the assistance of a caregiver is causing ... according to a new survey,released by Songbird Hearing, Inc. ( ...
... 12 Hyperion,Therapeutics, Inc. today reported completion ... trial designed to evaluate the safety, tolerability ... (sodium phenylbutyrate),the current standard of care in ... trial will be presented at an upcoming ...
... Spin-Off and Listing ... on NYSE ... Be Listed on NASDAQ, HONG KONG, Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- China,s leading,integrated ... Group", HKEx: 8180) today,announced the interim results of financial year 2008/09. During the ...
... 12 The Quantum Group,Inc. (Amex: QGP ... organization, in anticipation of a scheduled presentation to ... & CEO Noel J. Guillama later this morning, ... base to over 3,650 using the community,health systems ...
Other Medicine News:Health News:U.S. Teens Brimming With Self-Esteem 2Health News:U.S. Teens Brimming With Self-Esteem 3Health News:U.S. Teens Brimming With Self-Esteem 4Health News:Plight of Homeless Youth Will be Focus of Nov. 20 Times Square Vigil 2Health News:Plight of Homeless Youth Will be Focus of Nov. 20 Times Square Vigil 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 2Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 3Health News:Hearing Loss Presents a Significant Challenge for Rising Number of Caregivers 4Health News:Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders 2Health News:Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders 3Health News:Golden Meditech Releases FY2008/09 Interim Results 2Health News:Golden Meditech Releases FY2008/09 Interim Results 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 2Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 3Health News:The Quantum Group Announces Continued Growth of Patient Base and Preliminary Revenue Guidance 4
Freedom Cath® is a latex, self-adhering, one-piece catheter designed for everyday wear....
The Freedom Clear catheter is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for every day wear....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
Medicine Products: